GleamWall
中文EN

MLTX MoonLake Immunotherapeutics

Pharmaceutical Preparations · Nasdaq · SEC CIK 1821586 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-29.9%
TTM EPS YoY-9.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-81.6%
ROA-57.3%
ROIC (approx.)-384.1%
Asset turnover—

Leverage & solvency

Liabilities / assets29.4%
Debt / equity0.26x
Current ratio9.13x
Interest coverage-28.98x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$202.86M$112.77M
SG&A expense$41.97M$30.32M
Operating income-$244.83M-$143.09M
Interest expense$7.25M$0
Pretax income-$229.71M-$120.96M
Income tax$611,000$282,000
Net income-$227.32M-$118.94M
EBITDA-$242.22M-$141.71M
EPS (basic)-3.53-1.89
EPS (diluted)-3.53-1.89
Weighted avg. shares (diluted)64.46M62.87M
Balance sheet
Cash & equivalents$334.52M$180.43M
Short-term investments$59.45M$267.60M
Current assets$421.69M$474.29M
PP&E, net$577,000$722,000
Total assets$424.43M$477.93M
Current liabilities$45.48M$22.46M
Long-term debt$74.10M$0
Total debt$74.10M$0
Total liabilities$119.95M$24.54M
Shareholders' equity$304.48M$446.82M
Net debt-$260.42M-$180.43M
Cash flow statement
Operating cash flow-$196.01M-$116.59M
Capital expenditure$35,000$520,000
Free cash flow-$196.04M-$117.11M
Investing cash flow$202.99M-$205.60M
Financing cash flow$146.00M$51.31M
Depreciation & amortization$2.62M$1.39M
Stock-based compensation$12.90M$7.28M
Share buybacks—$50

Free plan shows the latest 2 periods; Pro shows all 5 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.